|
186 Products |
| 186 Products |
|
1696 Diseases |  |
94663 News |  |
| «12...1052105310541055105610571058105910601061106210631064» |
- |||| Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Trial completion, BRCA Biomarker, Metastases: An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer (clinicaltrials.gov) - Dec 28, 2011
P2, N=127, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Not yet recruiting --> Completed
- | montelukast / Generic mfg., fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg., fluticasone propionate inhalation powder / Generic mfg.
Trial completion: Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER) (clinicaltrials.gov) - Dec 28, 2011
P3, N=182, Completed, Sponsor: Milton S. Hershey Medical Center
Not yet recruiting --> Completed Active, not recruiting --> Completed
- | dexamethasone sodium phosphate-loaded RBC (EDS-EP) / Erydel
Enrollment change: Crodex: Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease (clinicaltrials.gov) - Dec 27, 2011
P3, N=51, Terminated, Sponsor: Erydel
Active, not recruiting --> Completed N=184 --> 51
- |||||| budesonide/formoterol / Generic mfg.
Enrollment open: A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents (clinicaltrials.gov) - Dec 27, 2011
P3, N=14500, Recruiting, Sponsor: AstraZeneca
N=184 --> 51 Not yet recruiting --> Recruiting
- | QVAR (beclomethasone dipropionate hydrofluoroalkane inhalation) / Teva
Trial completion: (CARE Network Trial - Treating Children to Prevent Exacerbations of Asthma (TREXA) (clinicaltrials.gov) - Dec 27, 2011
P3, N=288, Completed, Sponsor: Milton S. Hershey Medical Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Oncaspar liquid (pegaspargase) / Servier
New P4 trial: CTTNKTL-?/?: Treatment of Natural Killer/T Cell Lymphoma-?/? (clinicaltrials.gov) - Dec 27, 2011
P4, N=80, Recruiting, Sponsor: Mingzhi Zhang
- | Oncaspar liquid (pegaspargase) / Servier
New P4 trial: CTTNKTL-I/II: Treatment of Natural Killer/T Cell Lymphoma-I/II (clinicaltrials.gov) - Dec 27, 2011
P4, N=200, Recruiting, Sponsor: Mingzhi Zhang
- Zolinza (vorinostat) / Merck (MSD)
New P2 trial: Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy (clinicaltrials.gov) - Dec 27, 2011
P2, N=0, Withdrawn, Sponsor: Tiziana Marangon
- |||||||||| Varubi (rolapitant oral) / TerSera Therap, GSK
New P3 trial: Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy (clinicaltrials.gov) - Dec 26, 2011
P3, N=1369, Completed, Sponsor: Tesaro, Inc.
- |||||||||| Varubi (rolapitant oral) / TerSera Therap, GSK
New P3 trial, CINV: Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy (clinicaltrials.gov) - Dec 26, 2011
P3, N=555, Completed, Sponsor: Tesaro, Inc.
- ||||| fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
Trial initiation date, Head-to-Head: CAINAS SF: A Non- Inferiority Comparative Study Between Seretide® and Salmeterol/Fluticasone Eurofarma in Patients With Asthma (clinicaltrials.gov) - Dec 22, 2011
P3, N=334, Completed, Sponsor: Eurofarma Laboratorios S.A.
Active, not recruiting --> Completed Initiation date: Dec 2010 --> Aug 2011
- |||||||||| Varubi (rolapitant oral) / TerSera Therap, GSK
New P3 trial, CINV: Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy (clinicaltrials.gov) - Dec 22, 2011
P3, N=530, Recruiting, Sponsor: Tesaro, Inc.
- | fluticasone propionate ODT (APT-1011) / Ellodi Pharma
New P1/2 trial: A Six Month, Safety Follow-up Study in Eosinophilic Esophagitis Subjects Who Completed Study PR-021 (clinicaltrials.gov) - Dec 21, 2011
P1/2, N=24, Enrolling by invitation, Sponsor: Aptalis Pharma
- |||||||||| Breo Ellipta (fluticasone furoate / vilanterol) / GSK, Innoviva
New P3 trial, Combination therapy: Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry. (clinicaltrials.gov) - Dec 21, 2011
P3, N=311, Completed, Sponsor: GlaxoSmithKline
- |||||||||| Breo Ellipta (fluticasone furoate / vilanterol) / GSK, Innoviva
New P3 trial, Combination therapy: Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry (clinicaltrials.gov) - Dec 21, 2011
P3, N=313, Completed, Sponsor: GlaxoSmithKline
- | bortezomib / Generic mfg., dexamethasone / Generic mfg., pomalidomide / Generic mfg.
Clinical: Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 20, 2011
P1, N=48, Recruiting, Sponsor: Celgene Corporation
- ||| Bufomix Easyhaler (budesonide/formoterol dry powder inhaler) / Orion Corp
Trial completion: Comparison of Budesonide and Formoterol Absorption From Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler (clinicaltrials.gov) - Dec 20, 2011
P1, N=74, Completed, Sponsor: Orion Corporation, Orion Pharma
Initiation date: Dec 2010 --> Aug 2011 Not yet recruiting --> Completed
- ||||||| Breo Ellipta (fluticasone furoate / vilanterol) / GSK, Innoviva
Trial completion: Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Dec 20, 2011
P3, N=521, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Completed Active, not recruiting --> Completed
- Decadron (dexamethasone) / Merck (MSD)
Trial completion: Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant (clinicaltrials.gov) - Dec 19, 2011
P=N/A, N=40, Completed, Sponsor: OHSU Knight Cancer Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Rituxan (rituximab) / Roche
Enrollment closed, Combination therapy: UPCC 02408: Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas (clinicaltrials.gov) - Dec 18, 2011
P2, N=25, Active, not recruiting, Sponsor: University of Pennsylvania
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| ifosfamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion: Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI) (clinicaltrials.gov) - Dec 14, 2011
P=N/A, N=51, Completed, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Sancuso (granisetron) / Solasia
Trial suspension: Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer (clinicaltrials.gov) - Dec 13, 2011
P=N/A, N=60, Suspended, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed Not yet recruiting --> Suspended
- || dexamethasone / Generic mfg., metoclopramide / Generic mfg., palonosetron intravenous / Generic mfg.
New P3 trial: A clinical trial to investigate metoclopramide, dexamethasone or Aloxi for the prevention of nausea and vomiting occuring more than 24 hours after chemotherapy administration: the MEDEA trial (EUDRACT) - Dec 12, 2011
P3, N=450, Ongoing, Sponsor: VU University Medical Center Amsterdam
- |||| fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
Enrollment open: AUSTRI: SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma. (clinicaltrials.gov) - Dec 8, 2011
P4, N=11664, Recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Suspended Not yet recruiting --> Recruiting
- |||| fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
Enrollment open: VESTRI: 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old (clinicaltrials.gov) - Dec 8, 2011
P4, N=6200, Recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- fluocinonide / Generic mfg.
Enrollment open: Fluocinonide Cream in Treating Symptoms of Vaginal Dryness and Painful Sexual Intercourse In Patients With Breast Cancer Undergoing Hormone Therapy (clinicaltrials.gov) - Dec 8, 2011
P2, N=31, Recruiting, Sponsor: OHSU Knight Cancer Institute
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- oxaliplatin / Generic mfg., docetaxel / Generic mfg.
Enrollment open, Combination therapy, Metastases: KSWOG 2010-1: Docetaxel and Oxaliplatin Combination With Locally Advanced or Metastatic Biliary Tract Cancer (clinicaltrials.gov) - Dec 8, 2011
P2, N=53, Recruiting, Sponsor: Korean South West Oncology Group
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- hydrocortisone / Generic mfg.
Trial termination: Organ Donation and Hydrocortisone Treatment (clinicaltrials.gov) - Dec 7, 2011
P=N/A, N=38, Terminated, Sponsor: Kuopio University Hospital
Not yet recruiting --> Recruiting Recruiting --> Terminated; Routine use of corticoids became standard therapy
- |||| Tysabri (natalizumab) / Biogen
Clinical: RESTORE: Treatment Interruption of Natalizumab (clinicaltrials.gov) - Dec 7, 2011
P2, N=175, Completed, Sponsor: Biogen Idec
Recruiting --> Terminated; Routine use of corticoids became standard therapy Active, not recruiting --> Completed
- Kenalog-10 (triamcinolone acetonide) / BMS
Enrollment change: Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata (clinicaltrials.gov) - Dec 7, 2011
P2, N=30, Completed, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Active, not recruiting --> Completed N=50 --> 30
- Kenalog-10 (triamcinolone acetonide) / BMS
Trial completion: Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata (clinicaltrials.gov) - Dec 7, 2011
P2, N=30, Completed, Sponsor: University of Minnesota - Clinical and Translational Science Institute
N=50 --> 30 Recruiting --> Completed
- || budesonide/formoterol / Generic mfg.
Enrollment change: SURE: Symbicort Turbuhaler 30/60 Clinical Experience Investigation (clinicaltrials.gov) - Dec 5, 2011
P=N/A, N=3643, Completed, Sponsor: AstraZeneca
Recruiting --> Completed N=3000 --> 3643
- ||||| Zilretta (triamcinolone acetonide ER) / Pacira
New P2 trial: Study of FX006 in Patients With Osteoarthritis of the Knee (clinicaltrials.gov) - Dec 5, 2011
P2, N=229, Completed, Sponsor: Flexion Therapeutics, Inc.
- ||| budesonide/formoterol / Generic mfg.
Trial completion: SURE: Symbicort Turbuhaler 30/60 Clinical Experience Investigation (clinicaltrials.gov) - Dec 5, 2011
P=N/A, N=3643, Completed, Sponsor: AstraZeneca
N=3000 --> 3643 Recruiting --> Completed
- cisplatin / Generic mfg., pemetrexed / Generic mfg.
New P2 trial, Combination therapy, Metastases: PECULIAR: Pemetrexed and Cisplatin in Advanced Urothelial Carcinoma (clinicaltrials.gov) - Dec 5, 2011
P2, N=44, Recruiting, Sponsor: Asan Medical Center
- | Zilretta (triamcinolone acetonide ER) / Pacira
New P2 trial: Pharmacokinetic and Pharmacodynamic Study of FX006 in Patients With Osteoarthritis of the Knee (clinicaltrials.gov) - Dec 4, 2011
P2, N=24, Completed, Sponsor: Flexion Therapeutics, Inc.
- ||||| mycophenolate mofetil / Generic mfg.
Enrollment change: A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis. (clinicaltrials.gov) - Dec 4, 2011
P3, N=370, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Completed N=245 --> 370
- ganetespib (ADX-1612) / Aldeyra
New P1 trial: A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 4, 2011
P1, N=15, Recruiting, Sponsor: Emory University
- ||| fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
New P3 trial: Single Dose Study of the Fluticasone/Salmeterol (500/50 ?g) Administered With Elpenhaler (clinicaltrials.gov) - Nov 30, 2011
P3, N=28, Completed, Sponsor: Elpen Pharmaceutical Co. Inc.
- | New P1/2 trial: Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma (clinicaltrials.gov) - Nov 30, 2011
P1/2, N=76, Recruiting, Sponsor: Loyola University
- | Breo Ellipta (fluticasone furoate / vilanterol) / GSK, Innoviva
New P1 trial: Bioequivalence Study to Compare Fluticasone Furoate (FF) 1-strip Inhaler With FF 2-strip Inhaler and With FF/Vilanterol Combination (clinicaltrials.gov) - Nov 30, 2011
P1, N=30, Completed, Sponsor: GlaxoSmithKline
- Zolinza (vorinostat) / Merck (MSD)
New P1/2 trial: A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL (clinicaltrials.gov) - Nov 29, 2011
P1/2, N=16, Recruiting, Sponsor: Therapeutic Advances in Childhood Leukemia Consortium
- dexamethasone / Generic mfg.
Enrollment change, Surgery: Postoperative New-onset Atrial Fibrillation in Cardiac Surgery: DECS-PNAF Project (clinicaltrials.gov) - Nov 27, 2011
P4, N=80, Completed, Sponsor: UMC Utrecht
N=245 --> 370 N=164 --> 80
- ||||| fluticasone propionate inhalation powder / Generic mfg.
New P2 trial: A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids (clinicaltrials.gov) - Nov 22, 2011
P2, N=622, Completed, Sponsor: Teva Pharmaceutical Industries
- dexamethasone / Generic mfg.
Clinical: Cortisol Supression and Startle Responses in Posttraumatic Stress Disorder (PTSD) (clinicaltrials.gov) - Nov 21, 2011
P=N/A, N=150, Recruiting, Sponsor: Emory University
- ||||| Imbruvica (ibrutinib) / AbbVie, J&J
New P2 trial: Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Nov 21, 2011
P2, N=164, Recruiting, Sponsor: Pharmacyclics
- ||||| Empliciti (elotuzumab) / AbbVie, BMS
New P2 trial: Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Nov 21, 2011
P2, N=150, Recruiting, Sponsor: Bristol-Myers Squibb
- Torisel (temsirolimus) / Pfizer, Rituxan (rituximab) / Roche
Enrollment open, Combination therapy: Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL). (clinicaltrials.gov) - Nov 21, 2011
P1/2, N=63, Recruiting, Sponsor: The Lymphoma Academic Research Organisation
N=164 --> 80 Not yet recruiting --> Recruiting
- |||| Foradil Aerolizer (formoterol dry powder inhaler) / Novartis
Trial completion, Combination therapy: A Study of the Bronchodilator Effect of Formoterol Fumarate Used in Combination With Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P06476 AM2) (clinicaltrials.gov) - Nov 20, 2011
P2, N=92, Completed, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Recruiting --> Completed
- || Breo Ellipta (fluticasone furoate / vilanterol) / GSK, Innoviva
New P3 trial: Study to evaluate the effectiveness of fluticasone furoate/vilanterol delivered once daily via a Novel Dry Powder Inhaler (NDPI) compared with existing COPD maintenance therapy alone in subjects with Chronic Obstructive Pulmonary Disease. (EUDRACT) - Nov 20, 2011
P3, N=4232, Ongoing, Sponsor: GlaxoSmithKline Research & Development Ltd